Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

By A. Bardia, S. Hurvitz, S. Tolaney, D. Loirat, K. Punie, Mafalda Oliveira, A. Brufsky, S. Sardesai, K. Kalinsky, A. Zelnak and 20 more. 2021

Subfields: Cancer Research, Oncology

Citations in the corpus

• TROP2 expression in head and neck squamous cell carcinoma: association with the tumor immune microenvironment and clinical outcome (2026, unknown): “…target through the development of TROP2-directed antibody – drug conjugates, most notably sacituzumab govitecan, which has demonstrated signi fi cant clinical bene fi t in several epithelial malignancies including metastatic triple-negative breast cancer, NSCLC and urothelial carcinoma (46, 51 – 54).”